Simcere Pharmaceutical Group (HKSE:02096) Other Long-Term Liabilities : HK$668 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Other Long-Term Liabilities?

Simcere Pharmaceutical Group's other long-term liabilities for the quarter that ended in Dec. 2023 was HK$668 Mil.

Simcere Pharmaceutical Group's quarterly other long-term liabilities declined from Dec. 2022 (HK$579 Mil) to Jun. 2023 (HK$560 Mil) but then increased from Jun. 2023 (HK$560 Mil) to Dec. 2023 (HK$668 Mil).

Simcere Pharmaceutical Group's annual other long-term liabilities declined from Dec. 2021 (HK$686 Mil) to Dec. 2022 (HK$579 Mil) but then increased from Dec. 2022 (HK$579 Mil) to Dec. 2023 (HK$668 Mil).

Simcere Pharmaceutical Group Other Long-Term Liabilities Historical Data

The historical data trend for Simcere Pharmaceutical Group's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Other Long-Term Liabilities Chart

Simcere Pharmaceutical Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Simcere Pharmaceutical Group Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial							-	-	-	-	-

Simcere Pharmaceutical Group Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Simcere Pharmaceutical Group Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group (HKSE:02096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Other Long-Term Liabilities

Traded in Other Exchanges

S2P:Germany

Address

No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042

Website

https://www.simcere.com

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Executives

Wang Xi	2305 Beneficiary of a trust
Ren Jinsheng	2202 Interest of your spouse
Right Wealth Holdings Limited	2501 Other
Wang Xi	2501 Other
Simcere Investments Group Limited	2501 Other
Excel Investments Group Limited	2501 Other
Simcere Pharmaceutical Holding Limited	2501 Other
Simcere Holding Limited	2501 Other
Artking Global Limited	2501 Other
Ren Zhen	2501 Other
Ren Yong	2501 Other
Ren Weidong	2501 Other
Peng Suqin	2501 Other
P&h Holdings Group Ltd.	2501 Other
Li Shimeng	2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines